"And then we have an additional fracture system that is scheduled for launch next year in the hip line, and we have another iteration of the Optecure, what we call phasic version of our DBM bone paste in Biologics business unit, as well as a bone marrow aspirate concentrate system, which should launch in the second half of next year."